<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Coagulo Medical Technologies, Inc. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=36716></link><description><![CDATA[Coagulo Medical Technologies, Inc. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Thu, 14 May 2026 04:16:05 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2020/12/12_3554238800_20201223132646_5463467923.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Coagulo Medical Technologies Announces $6.5 Million in Financing to Accelerate Delivery of Disruptive Coagulation Diagnostics Platform]]></title><link>https://www.newswire.co.kr/newsRead.php?no=916457</link><description><![CDATA[CAMBRIDGE, Mass.--(Business Wire/Korea Newswire)--Coagulo Medical Technologies, an MIT-born startup that has developed the world’s first precision-medicine platform for comprehensive and targeted blood clotting management, today announced it has raised $6.5 million in financing from 20/20 HealthCare Partners, Sands Capital, Good Growth Capital, IAG Capital Partners and private investors. The Bo...]]></description><pubDate>Wed, 23 Dec 2020 13:45:00 +0900</pubDate></item><item><title><![CDATA[코아귤로 메디컬 테크놀로지스, 획기적 혈액응고 진단 플랫폼의 상용화를 가속화하기 위한 650만달러의 자금 조달 발표]]></title><link>https://www.newswire.co.kr/newsRead.php?no=916458</link><description><![CDATA[케임브리지, 매사추세츠--(Business Wire/뉴스와이어)--미국 매사추세츠 공과대학(MIT)에서 창업해 혈액응고를 종합적이고 표적을 대상으로 관리하는 세계 최초의 정밀 의약 플랫폼을 개발한 스타트업 코아귤로 메디컬 테크놀로지스(Coagulo Medical Technologies, 이하 ‘코아귤로’)가 20/20 헬스케어 파트너스(20/20 HealthCare Partners), 샌즈 캐피털(Sands Capital), 굿 그로스 캐피털(Good Growth Capital), IAG 캐피털 파트...]]></description><pubDate>Wed, 23 Dec 2020 13:45:00 +0900</pubDate></item></channel></rss>